RITE AID CORPORATION et al v. CEPHALON, INC. et al

Filing 90

MEMORANDUM AND OPINION. SIGNED BY HONORABLE MITCHELL S. GOLDBERG ON 6/8/17. 6/9/17 ENTERED & E-MAILED.(fdc)

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA
__________________________________________ ___________________________________
:
APOTEX, INC.,
:
CIVIL ACTION
Plaintiff,
:
:
v.
:
No. 2:06-cv-2768
:
CEPHALON, INC., et al.,
:
Defendants.
:
__________________________________________:___________________________________
:
GIANT EAGLE, INC.,
:
CIVIL ACTION
Plaintiff,
:
:
v.
:
No. 2:10-cv-5164
:
CEPHALON, INC., et al.,
:
Defendants.
:
__________________________________________:___________________________________
:
WALGREEN CO., et al.,
:
CIVIL ACTION
Plaintiffs,
:
:
v.
:
No. 2:09-cv-3956
:
CEPHALON, INC., et al.,
:
Defendants.
:
__________________________________________:___________________________________
:
RITE AID CORPORATION, et al.,
:
CIVIL ACTION
Plaintiffs,
:
:
v.
:
No. 2:09-cv-3820
:
CEPHALON, INC., et al.,
:
Defendants.
:
__________________________________________:___________________________________

1

Goldberg, J.

June 8, 2017
MEMORANDUM OPINION

In Federal Trade Commission v. Actavis, 133 S. Ct 2223 (2013), the Supreme Court
wrestled with the complexities of how a reverse-payment patent litigation settlement fits within
an antitrust context. Ultimately concluding that a rule of reason analysis applies, the Court
stressed that the “structuring of the present rule-of-reason antitrust litigation” must be left to the
trial court. This Opinion sets forth such a structure where the relevant patent is found to be
invalid and not infringed several years after the reverse-payment settlement agreements were
executed.
After careful consideration and noting that there is no precedential guidance on this issue,
I conclude that prior findings of patent invalidity and non-infringement made after the reversepayment settlement agreements are irrelevant to a rule of reason analysis. However, I conclude
that the prior patent ruling is relevant to Plaintiffs’ antitrust causation showing and, in this
context, the ruling is admissible under Federal Rule of Evidence 403.
I.

FACTUAL BACKGROUND AND PROCEDURAL HISTORY
The case before me involves allegations that four reverse-payment settlement agreements

entered into by a brand-name drug manufacturer, Cephalon, Inc., and four generic drug
companies constitute antitrust violations under the Sherman Act.1 Plaintiffs claim that these
settlement agreements were executed for the purpose of delaying competition from generic
versions of the brand-name pharmaceutical, Provigil. Defendants, signatories to the settlement
1

These agreements were entered into by Defendant, Cephalon, Inc. (“Cephalon”), the
manufacturer of brand-name Provigil, and the following Defendant generic drug manufacturers:
Barr Pharmaceuticals, Inc. (“Barr”); Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc.
(collectively “Mylan”); Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA,
Inc. (collectively “Teva”); and Ranbaxy Laboratories, Ltd. and Ranbaxy Pharmaceuticals, Inc.
(collectively “Ranbaxy”) (collectively referred to as the “Generic Defendants”).
2

agreements, maintain that the agreements were pro-competitive and legitimate settlements of
litigation involving Provigil and its related patent.
As a result of various settlements and the procedural postures of other related cases, the
only plaintiffs who will participate in the upcoming trial are Apotex, Inc., a generic competitor,
and a group of owners and operators of retail pharmacies. Over the course of this litigation, these
plaintiffs have been referred to as “Individual Plaintiffs,” “Retailer Plaintiffs,” “Opt-Out
Plaintiffs” and “Merchant Plaintiffs.” The only defendants in the upcoming trial are generic
manufacturers Mylan and Ranbaxy.2
a. Relevant Regulatory Background
Under the Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No.
98–417, commonly known as the Hatch-Waxman Act, generic manufacturers are permitted to
file an Abbreviated New Drug Application (“ANDA”) when seeking approval from the Food and
Drug Administration to market a generic version of an approved drug. An ANDA filer is able to
adopt the safety and efficacy studies that the FDA previously approved in connection with a
brand-name drug’s New Drug Application. See Caraco Pharm. Labs., Ltd. v. Forest Labs., Inc.,
527 F.3d 1278, 1282 (Fed. Cir. 2008).
In filing an ANDA, a generic manufacturer must demonstrate that its generic product and
the approved brand-name drug share the same active ingredients and are bioequivalent. As to any
patents covering the brand-name drug, the generic manufacturer must certify: (1) that the
relevant patent information has not been filed with the FDA; (2) that any such patent has expired;
(3) the date that such patent will expire; or (4) “that such patent is invalid or will not be infringed
by the manufacture, use, or sale of the new drug for which the application is submitted.” Id. at
2

More specifically the upcoming trial involves the claims Apotex has brought against Ranbaxy
and Mylan and the claims the Retailer Plaintiffs have brought against Ranbaxy.
3

1282-83 (quoting 21 U.S.C. § 355(j)(2)(A)(vii)). If a generic manufacturer seeks to market a
generic drug prior to the expiration of patents covering the brand drug, it must file a certification
under 21 U.S.C. § 355(j)(2)(A)(vii)(IV)—i.e., a “Paragraph IV certification.” Id. at 1283. The
filing of a Paragraph IV ANDA constitutes an act of patent infringement, often prompting the
patent holder to file a lawsuit. Actavis, 133 S. Ct. at 2228 (citing 35 U.S.C. § 271(e)(2)(A)).
If the patent holder files an infringement lawsuit within forty-five days of a generic
manufacturer’s ANDA filing, the FDA is barred from approving the generic’s ANDA for a
period of thirty months. 21 U.S.C. § 355(j)(5)(B)(iii). If the case is resolved during the thirty
month stay, the FDA will take action on the ANDA consistent with the court’s judgment.
Actavis, 133 S. Ct. at 2228. However, if the case is not resolved during that period, the FDA may
approve the ANDA, at which point the generic company decides whether to sell its product “atrisk” of incurring damages should the infringement case result in a judgment in favor of the
patent holder. Id.
b. Relevant Factual Background
Cephalon held U.S. Reissue Patent No. 37,516 (RE ‘516) claiming a specific formulation
of modafinil—a molecule with wakefulness-promoting properties. The RE ‘516 patent covered
Cephalon’s drug, Provigil, and, when combined with a number of FDA regulatory exclusivity
periods Cephalon had obtained, it had the potential to protect Provigil from generic competition
through April 6, 2015.
On December 24, 2002, the first day allowed by law, the Generic Defendants sought
permission from the FDA to market generic versions of Provigil. In doing so, the four generic
drug manufacturers filed Paragraph IV certifications attesting that the RE ‘516 patent was either
invalid or not infringed by their proposed generic Provigil products. In response to these

4

certifications, Cephalon filed suit against the Generic Defendants for patent infringement. The
parties have referred to these lawsuits as the “Paragraph IV litigation.”
Between December 2005 and February 2006, the Paragraph IV litigation settled, with
Cephalon paying the Generic Defendants millions of dollars in return for various business
arrangements and, most importantly for purposes of this case, promises from each of the Generic
Defendants to drop their respective invalidity contentions and not market a generic version of
Provigil until April 6, 2012.
Pursuant to another provision of the Hatch-Waxman Act, no other company could sell
generic Provigil until six months after the settling Generic Defendants began to market their
versions. Thus, in order to be allowed to enter the market sooner, a competing generic—here,
Apotex—would need to receive a court determination that the RE ‘516 patent was invalid or not
infringed.
In the cases before me, the Federal Trade Commission, two putative classes of plaintiffs,
the Retailer Plaintiffs and Apotex brought Actavis antitrust claims against all Defendants.
Apotex also brought claims for Walker Process fraud and sham litigation against Cephalon and
also sought a declaratory judgment invalidating the RE ‘516 Patent.
Appreciating that resolution of the antitrust claims could take many years, I commenced a
patent trial in 2011. After submission of extensive testimony, I found merit in Apotex’s position
and declared Cephalon’s patent invalid on several grounds and also unenforceable as a result of
Cephalon’s inequitable conduct during the procurement process. See Apotex, Inc. v. Cephalon,
Inc., 2011 WL 6090696 (E.D. Pa. Nov. 7, 2011). This ruling was subsequently affirmed by the
United States Court of Appeals for the Federal Circuit, Apotex, Inc. v. Cephalon, Inc., 500 Fed.

5

App’x 959 (Fed. Cir. 2013), and certiorari was denied by the United States Supreme Court. See
134 S. Ct. 825 (2013).
As the antitrust case progressed, the parties subsequently litigated whether the patent
ruling had a preclusive effect on certain arguments Cephalon sought to present in defending
against the antitrust claims brought against it. See King Drug Co. of Florence v. Cephalon, Inc.,
2014 WL 982848 (E.D. Pa. Mar. 13, 2014); F.T.C. v. Cephalon, Inc., 36 F. Supp. 3d 527 (E.D.
Pa. 2014) (collectively, “collateral estoppel decisions”). These collateral estoppel decisions
primarily dealt with whether Cephalon was precluded from relitigating issues decided in the
2011 patent proceedings and presenting evidence that implicated those previously litigated
issues.
After extensive discovery and further motion practice, a liability trial—including the
Apotex and the Retailer Plaintiffs’ cases—was scheduled to begin on February 2, 2016. Prior to
that date, the parties filed multiple motions in limine regarding what role, if any, the prior patent
findings should play in the upcoming antitrust trial. Many of the parties’ Daubert motions also
touched on this issue.
In ruling on a number of Plaintiffs’ Daubert motions, I summarized how the collateral
estoppel decisions would shape the antitrust trial in general and the Walker Process claim against
Cephalon in particular as follows:
With trial pending, it may be useful to restate here which issues
have been decided and may not be revisited: (1) the RE ‘516 patent
is invalid due to the on-sale bar, derivation and obviousness; and
(2) the materiality prong of Walker Process fraud has been
established. Consequently, and as will be explained in greater
detail infra, any expert opinions contrary to these holdings will not
be permitted.
It is also my intention to explain to the jury that these issues have
been previously decided, must be accepted, and are not for their
6

consideration. This explanation will come by way of instructions
prior to opening statements and the taking of testimony. I will, of
course, accept input from counsel as to how these concepts should
be conveyed to the jury, but care will be taken to ensure that
Defendants’ rights in defending the antitrust allegations will be
protected.
King Drug Co. of Florence, Inc. v. Cephalon, Inc., 2015 WL 6750899, at *3-4 (E.D. Pa. Nov. 5,
2015). I also noted that my collateral estoppel decisions made clear that “[t]he fact that the patent
was found invalid in the 2011 Apotex patent litigation should have no bearing on the proofs
necessary to hold the Generic Defendants liable for antitrust violations . . . [and] [t]he Generic
Defendants will still be able to argue, should they so choose, that settlement was procompetitive, and that they were unaware of Cephalon’s alleged fraud or the invalidity of the
patent.” Id. at *3 (quoting King Drug Co. of Florence v. Cephalon, Inc., 2014 WL 982848, at
*13).
In the lead up to the February 2016 trial date, Defendants appealed my ruling granting
certification of a Direct Purchaser class. In light of that appeal, the United States Court of
Appeals for the Third Circuit stayed the February trial date as to all parties. As such, many of the
motions in limine were not resolved at that time and were still pending when a new trial date was
set after the Third Circuit issued its decision on the class certification appeal and the stay was
lifted.
In the interim, several parties settled and, as a result, the make-up of the parties now
proceeding to trial and the claims at issue have changed considerably. In short, Cephalon and the
Walker Process claim brought against it are no longer part of the case. The prior collateral
estoppel decisions as well as the parties’ motions regarding the patent ruling were filed when
Cephalon was still part of the case. Consequently, in many ways the prior collateral estoppel
decisions and the parties’ previously submitted arguments no longer fit the facts of the case as
7

presently configured. However, the parties’ recent submissions have provided additional clarity
and the issue as to the admissibility of the prior patent ruling is now finally ripe for final
resolution.
II.

LEGAL STANDARDS
Evidence is relevant if it “(a) has any tendency to make a fact more or less probable than

it would be without the evidence; and (b) the fact is of consequence in determining the action.”
Fed. R. Evid. 401. “The court may exclude relevant evidence if its probative value is
substantially outweighed by a danger of one or more of the following: unfair prejudice,
confusing the issues, misleading the jury, undue delay, wasting time, or needlessly presenting
cumulative evidence.” Fed. R. Evid. 403. The court is afforded “very substantial discretion” in
conducting the Rule 403 balancing test. United States v. Long, 574 F.2d 761, 767 (3d Cir. 1978).
III.

DISCUSSION
At the recent pretrial conference, the parties again presented argument regarding the

admissibility of the prior patent ruling. Prior to that conference, I had understood Plaintiffs’
position to be that the prior patent ruling was relevant and admissible in the context of the entire
trial. However, through the parties’ pretrial memoranda and argument presented at pretrial
conference, it became clear that Plaintiffs contend that the prior patent ruling is specifically
relevant and admissible in the context of causation. Defendants have continued to maintain that
any mention of the outcome of the patent trial—in either the rule of reason or causation portion
of trial—would be highly prejudicial.
In light of this narrowed argument, I invited the parties to submit additional briefing on
whether the prior patent ruling is relevant and otherwise admissible in the context of the
causation part of the case.

8

a. Admissibility of Prior Patent Ruling in the Antitrust Violation Context
Defendants have consistently argued that, under Actavis, the prior patent ruling is
irrelevant to Plaintiffs’ claims because that ruling postdates the settlement agreements by several
years. Defendants assert that the parties’ views regarding the patent’s strength or weakness and
how those views impacted the decision to enter into the challenged settlement agreements should
be examined on an ex ante basis, thus excluding a subsequent ruling on the patent.
After reviewing the additional arguments the parties recently presented, I agree with
Defendants that the patent ruling, which occurred approximately five years after the settlement
agreements were executed, is not admissible to establish whether Defendants violated the
antitrust laws under an Actavis rule of reason framework. My conclusion rests primarily on the
fact that the Actavis rule of reason analysis is focused on whether the settlements were
reasonable at the time they were entered into – in late 2005 and early 2006.
In fact, in analyzing the admissibility of expert testimony, I previously held that the
relevant rule of reason analysis is conducted on an ex ante basis, that is, as of the time the
settlements were executed. See King Drug Co. of Florence, Inc., 2015 WL 6750899, at *12
(“[E]xperts should limit their testimony to exploration of the infringement opinions and
arguments raised by the parties at the time of the Paragraph IV litigation on an ex ante basis”);
see also King Drug Co. of Florence, Inc., 2015 WL 5783603, at *6. After reexamination of these
rulings, I stand by that conclusion, notwithstanding the fact that the parties proceeding to trial
have been significantly pared down.
Legal scholars and other courts presented with this issue concur with the ex ante
interpretation of Actavis. See Aaron Edlin, et al., The Actavis Inference: Theory and Practice, 67
Rutgers U.L. Rev. 585, 617 (2015) (“[T]he antitrust analysis of a reverse-payment settlement

9

should be made on an ex ante basis, as of the date of the settlement itself.”); In re Wellbutrin XL
Antitrust Litig., 133 F. Supp. 3d 734, 753 (E.D. Pa. 2015) (“In conducting the rule of reason
analysis, the Court will evaluate the [ ] Settlement’s reasonableness at the time it was entered
into.”); In re Lipitor Antitrust Litig., 46 F. Supp. 3d 523, 544 (D.N.J. 2014) (“In this case, in
order to approximate the amount of Pfizer’s alleged consideration to Ranbaxy, it is necessary to
consider the monetary value of Pfizer’s claim at the time of the settlement.”). This interpretation
is also consistent with the general principle that “the reasonableness of agreements under the
antitrust laws are to be judged at the time the agreements are entered into.” Valley Drug Co. v.
Geneva Pharm., Inc., 344 F.3d 1294, 1306 (11th Cir. 2003).
Against this backdrop, I conclude that the patent ruling, which postdates the contested
settlement agreements, is irrelevant under the ex ante framework mandated by the Actavis rule of
reason analysis. See Aaron Edlin, et al., The Actavis Inference: Theory and Practice, 67 Rutgers
U.L. Rev. 585, 586 (2015) (“The antitrust question depends upon the ex ante prospects in patent
litigation and not ex post litigation of the patent by a patent court or by the antitrust court
considering the settlement. Litigating the patent is thus of limited probative value and not
dispositive regarding a potential antitrust violation.”)
In addition to the relevance question, Defendants also argue that introduction of the prior
patent ruling would result in significant jury confusion and unfair prejudice. Given the ex ante
focus of the Actavis rule of reason framework, and to the extent that a Rule 403 analysis applies,
I agree with Defendants that whatever probative value the patent rulings would have in the rule
of reason portion of the case would be substantially outweighed by the risk of jury confusion and
unfair prejudice. The fact that the patent was found to be invalid several years after the
settlement agreements were finalized has little bearing on whether the decisions to enter into

10

those agreements were reasonable in light of the circumstances in existence at that time. I am
persuaded that the jury will be unable to reconcile and abide by that temporal nuance if presented
with evidence that the patent was invalidated several years after the agreements in question were
reached. This reality may also result in unfair prejudice to Defendants.
As noted above, I conclude that the patent ruling is not relevant in an ex ante rule of
reason analysis. But, even if relevant, I conclude that whatever marginal probative value the
2011 patent ruling may have in the context of the rule of reason analysis is substantially
outweighed by the risk of jury confusion and unfair prejudice. Whether the prior patent ruling is
admissible in the context of causation is a separate question.
b. Admissibility of the Prior Patent Ruling in the Antitrust Causation Context
Causation is an essential element of a private plaintiff’s antitrust case. Out Front Prods.,
Inc. v. Magid, 748 F.2d 166, 169 (3d Cir. 1984). To demonstrate causation, the Clayton Act
requires plaintiffs to prove that their injuries were caused “by reason of” anticompetitive
conduct. 15 U.S.C. § 15(a). “The ‘by reason of’ language requires both a showing that
defendant’s actions were the but-for and the proximate cause of the injury.” In re Wellbutrin, 133
F. Supp. 3d at 763(citing Assoc. Gen. Contractors of Calif. v. California State Council of
Carpenters, 459 U.S. 519, 531 (1983)). In the context of a reverse-payment settlement claim,
plaintiffs must prove that the settlements caused a delay in generic competition. See King Drug
Co. of Florence, 88 F. Supp. 3d 402, 421-23 (E.D. Pa. 2015).
Plaintiffs have offered two theories as to how the reverse-payment settlements delayed
generic entry, thereby causing economic injury. Plaintiffs describe these two theories as follows:
But for the Cephalon-Mylan and Cephalon-Ranbaxy reversepayment agreements, [1] Mylan and/or Ranbaxy would have
launched at-risk [or 2] defeated the ‘516 patent, triggering their
180-day exclusivity. Under those circumstances, Apotex would
11

have obtained final FDA approval and launched its own generic
modafinil product at least when the first filers’ 180-day exclusivity
expired.
(Dkt. No. 06-2768, Doc. No. 1095, Pls.’ Pretrial Mem. p. 28.)
Relevant to the question presently before me is the first theory of causation. Under that
theory, Plaintiffs argue that but for the settlements agreements, Mylan or Ranbaxy would have
pursued the Paragraph IV litigation and launched their generic products after the expiration of
the automatic thirty month stay, but prior to judgment being entered in the Paragraph IV
litigation.
Plaintiffs explain that the prior patent rulings are relevant to this at-risk launch theory of
causation. Plaintiffs raised this argument in response to two questions included on Defendants’
proposed jury verdict form. These questions are:
Have Plaintiffs proved that if Cephalon and Ranbaxy had not
entered into their patent litigation settlement, Ranbaxy would have
lawfully launched an FDA-approved generic Provigil product in
2006?
...
Have Plaintiffs proved that if Cephalon and Mylan had not entered
into their patent litigation settlement, Mylan would have lawfully
launched an FDA-approved generic Provigil product in 2006?
(Dkt. No. 06-2768, Doc. No. 1119-4, Defs.’ Proposed Verdict Form, pp. 6 and 9.) Plaintiffs
argued that the inclusion of the term “lawful” indicated Defendants’ position that Plaintiffs must:
offer evidence from which the jury could conclude that the patent
was invalid or not infringed and [ ] therefore an at-risk entry
would've been lawful, because of course if the at-risk entry was
unlawful the defendants will argue then the entry didn’t cause any
damages, because in the end they would not be allowed to stay on

12

the market.
(Pretrial Conf., May 16, 2017, Tr. 45:16:21.) Based on all of the above, Plaintiffs urge that the
prior patent ruling is highly probative and relevant to the question of whether an at-risk launch
would have been lawful.
After hearing Plaintiffs’ argument, counsel for both Mylan and Ranbaxy stated that they
were willing to withdraw the word “lawful” from their proposed verdict form. (Id. at 55:16-22;
56:22-57:1.) Plaintiffs convincingly responded that even if that word was removed from the
proposed verdict form, the issue would not be resolved because they still must prove that their
presence in the market would have been lawful. Plaintiffs explain that the only two courts to
have considered the elements of an at-risk launch theory of causation have both held that a
plaintiff must demonstrate that a generic defendant’s decision to launch at-risk would be
“lawful”—meaning that the brand company’s patent is invalid or not infringed by the generic
product launched at-risk, In re Nexium (Esomeprazole) Antitrust Litigation, 842 F.3d 34 (1st Cir.
2016) and In re Wellbutrin XL Antitrust Litigation, 133 F. Supp. 3d 734 (E.D. Pa. 2015). After
careful consideration of these decisions, I agree that Nexium and Wellbutrin support Plaintiffs’
position.
In Nexium, the plaintiffs offered multiple arguments, including an at-risk launch theory,
regarding how the defendants’ reverse-payment settlements caused harm. 842 F.3d at 61-62. At
the close of plaintiffs’ case, the district court granted defendants’ motion for judgment as a
matter of law with regard to any “causal mechanism” based on patent invalidity, finding “no
adequate evidence that any of [the Nexium] patents would be adjudicated invalid.” Id. at 49.
On appeal, the United States Court of Appeals for the First Circuit held that the district
court “did not err by requiring some evidence of the patents’ invalidity or non-infringement

13

before allowing the plaintiffs to pursue an at-risk launch theory” of causation because without
such evidence the underlying patents would have operated as an independent bar to the generic’s
launch. Id. at 63. The First Circuit rejected the plaintiffs’ argument that “they should not have to
prove patent invalidity or noninfringement to be able to present their at-risk launch causation
theory.” Id. at 62-64.
In reaching its conclusion, the First Circuit recognized that the district court’s judgment
as a matter of law ruling on causation did not prevent nor prejudice plaintiffs’ ability to offer
evidence regarding the assessment of risk in the context of showing an antitrust violation under
the Actavis rule of reason framework. Id. at 64.
Like Nexium, the plaintiffs in Wellbutrin also sought to proceed on an at-risk launch
theory of causation. The district court granted defendants’ motion for summary judgment on the
issue of causation because the plaintiffs offered no evidence of invalidity or non-infringement in
support of their at-risk launch theory. 133 F. Supp. 3d at 764-767. Citing City of Pittsburgh v.
West. Penn Power Company, 147 F.3d 256 (3d Cir. 1998), the district court noted that “an
independent regulatory scheme can cut off the necessary chain of causation.” Wellbutrin, 133 F.
Supp. 3d at 763-764.
Applying that principle in the context of Plaintiffs’ at-risk launch theory of causation, the
court reasoned that “the existence of a valid and uninfringed patent would interfere with the
plaintiffs’ chain of causation: a valid patent independently precludes competition apart from any
agreement and an ‘at-risk’ launch is unlawful absent a later finding of patent invalidity or noninfringement.” Id. at 764-65 (emphasis added) (internal citations and alterations omitted). As
such, the court held that to succeed under an at-risk theory of causation, the plaintiffs would have
to show that reverse-payment settlements prevented generic entry, rather than the underlying

14

patents and, in order to do so, the plaintiffs would have to offer evidence that the underlying
patent would have been invalidated or the generic product would not have infringed the
underlying patent. Id. at 765. As the plaintiffs had offered no such evidence, the district court
entered summary judgment in defendants favor. Id. at 764-67.
The clear import of Nexium and Wellbutrin is that a plaintiff must offer some evidence of
non-infringement or patent invalidity in order to proceed on an at-risk launch theory of
causation. The fact that the patent in question has been found to be invalid and non-infringed is
relevant evidence on that required proof.
Against this backdrop, I agree with Plaintiffs that evidence of a patent’s subsequent
invalidation is highly probative to the lawful launch question. Additionally, nothing in the albeit
limited case law suggests that the strict ex ante lens that applies to the rule of reason under
Actavis must also apply to the question of causation.3 In light of the foregoing, I conclude that
the prior patent ruling is highly probative in the context of Plaintiffs’ at-risk launch theory of
causation.
c. Trial Structure
This case is unique because the patent was found to be invalid after settlement of the
Paragraph IV litigation but prior to the antitrust trial—a procedural posture that all involved have
endeavored to grapple with. As far as I am aware, this case will be the second Actavis reversepayment settlement case to go to trial. Consequently, there is little guidance on how to structure
3

The Supreme Court did not address causation in Actavis. This silence is likely attributable to
the fact that the plaintiff was the Federal Trade Commission and the claims were equitable in
nature. In antitrust cases, the FTC is held to a less stringent causation standard than private
plaintiffs. See 15 U.S.C. § 45 (The FTC need only prove that a defendant’s conduct is “likely to
cause” injury). As such, although the Actavis Court stated that “it is normally not necessary to
litigate patent validity to answer the antitrust question,” 133 S. Ct. at 2236, that statement does
not address a private plaintiff’s causation requirement nor does it preclude examination of the
validity of the patent where necessary.
15

this case. In Actavis, the Court allowed wide discretion for lower courts to structure rule of
reason antitrust litigation, explaining:
As in other areas of law, trial courts can structure antitrust
litigation so as to avoid, on the one hand, the use of antitrust
theories too abbreviated to permit proper analysis, and, on the
other, consideration of every possible fact or theory irrespective of
the minimal light it may shed on the basic question—that of the
presence of significant unjustified anticompetitive consequences.
We therefore leave to the lower courts the structuring of the
present rule-of-reason antitrust litigation.
133 S. Ct. at 2238 (internal citations omitted).
Given the discretion conferred by Actavis, and my legal conclusions regarding the
admissibility of the prior patent ruling, I conclude that the upcoming liability trial will be divided
into two phases. The first phase will involve only proofs regarding the alleged antitrust violations
under the rule of reason. The jury verdict form will contain questions pertaining only to the
antitrust violation under the rule of reason analysis. Consistent with my conclusions set forth
above, the prior patent ruling will not be mentioned by the court, witnesses or attorneys during
this first phase.
If the jury answers the violation questions in Plaintiffs’ favor, a second phase involving
causation and injury will commence. There, I will inform the jury that the patent was determined
to be invalid in a subsequent proceeding.4 However, in light of Defendants’ legitimate concerns
regarding prejudice, the jury will not be told that I personally made that prior ruling or that it was

4

I have also considered Plaintiffs’ position that all findings of fact from the invalidity portion of
the patent trial be read to the jury by way of stipulation. This is an overly expansive position.
Doing so would place a heavy hand on the unfair prejudice side of the scale. I must balance the
need for the jury to understand how these facts fit in an antitrust case with the risk of unfair
prejudice to the Defendants. Such an extensive recitation is unnecessary and the probative value
is substantially outweighed by the risk of jury confusion and/or unfair prejudice under Rule 403.
16

affirmed on appeal. Rather, I will generally inform the jury that these issues were decided in a
prior proceeding without identifying the decision maker.
A jury instruction will also be given that emphasizes that Mylan and Ranbaxy were not
involved in the patent procurement process or the subsequent finding of invalidity. This jury
instruction will also explain that admission of this evidence is for a specific and limited
purpose—i.e., Plaintiffs’ causation theory—and that it is just one piece of evidence that may be
considered on the issue of causation. These additional instructions will also decrease the risk of
unfair prejudice.
During this phase of the trial, counsel will be given an opportunity to present short
opening and closing statements. If relevant, evidence from the first phase may be incorporated
and other relevant causation/injury evidence may also be offered. Specific causation and injury
questions will then be posed to the jury.
This process adequately addresses Defendants’ prejudice concerns.5 Defendants argued
that they will be unfairly prejudiced because they were not participants in the prior patent
proceedings. However, that argument misses the mark because neither Defendant was the patent
holder and thus could not logically be a part of the patent proceeding. Surely, both the Court and
counsel can clearly explain that point to the jury. Defendants are also free to present evidence of
5

Following the pretrial conference, I provided Defendants with yet another opportunity to
explain their positions regarding prejudice. Both Mylan and Ranbaxy submitted further briefing.
I have carefully considered those supplemental briefs but, as explained above, the risk of unfair
prejudice, as articulated by Defendants, does not substantially outweigh the probative value in
the context of causation.
I also note that Defendants argued that the jury will undoubtedly assume that a judge invalidated
the patent and that this assumption will result in unfair prejudice. I agree with Plaintiffs that this
argument assumes that evidence is unfairly prejudicial if it is highly probative and supports the
opposing parties’ position. Even assuming this assumption constitutes “unfair prejudice,” the
supposed risk identified by Defendants does not substantially outweigh the probative value of the
evidence.
17

other considerations that indicate that Defendants would not have launched at-risk and may
argue that, when evaluating the evidence of causation, the jury should not afford the prior patent
ruling any weight in light of the timing of events.
IV.

CONCLUSION
For the foregoing reasons, I conclude that the liability portion of the trial will be divided

into two phases – violation and causation – and only during the second phase regarding causation
will the jury be informed that the relevant patent was invalidated in a proceeding which occurred
after the Paragraph IV litigation settled. An appropriate Order follows.

18